Aquapharm Bio-Discovery Ltd Enters a Collaboration Deal with DowpharmaSM Contract Manufacturing Services
Aquapharm Bio-Discovery Ltd. (Aquapharm), a UK marine biotechnology company developing, amongst other things, nutraceutical and anti-infective drug candidates from marine natural products, has entered a collaboration with DowpharmaSM contract manufacturing services, a business unit of The Dow Chemical Company, which will allow it to explore Aquapharm's library of novel marine micro organisms for new bio-catalysts for pharmaceutical applications. Dow is paying Aquapharm for the preparation of hundreds of sample extracts from the organisms for Dow to examine. In the event Dow desires to commercialize, the parties will enter into a license under which Aquapharm expects to receive a royalty.
Aquapharm Bio - Discovery Ltd. was founded in 2000 in Scotland by Dr. Andrew Mearns Spragg and Dr. Kathryn Fraser two Ph.D. graduates of Heriot-Watt University, Edinburgh. The company has a substantial collection of unique marine bacteria & fungi obtained from samples collected from diverse and extreme marine habitats, including the arctic and the deep sea, and it uses these to develop new biologically active natural products for pharmaceutical, nutraceutical and industrial applications. Aquapharm's patented technology base has the ability to manipulate marine microbial communities to stimulate the development and production of new molecules of pharmaceutical potential.
Other news from the department business & finance
